Search PubMed⌕ Search

Biomedical subjects

A Dupont

Publications and source records attributed to A Dupont.

410 records · Page 23Linked to original sources
PubMedDate not supplied

[Toxoplasma encephalitis in acquired immunodeficiency syndrome].

Several outbreaks of fatal opportunistic infections and tumors have recently been reported among homosexual men in the United States. Almost all patients had evidence of cellular immunodeficiency. We have studied a French homosexual man with fatal central nervous system toxoplasmosis. Morphological features (light and electron microscopy) of toxoplasma encephalitis are described.

Acquired Immunodeficiency Syndrome↗
PubMedDate not supplied

[Glomerular nephropathy and schistosomiasis (author's transl)].

Glomerular lesion appears frequently in patients with S. mansoni or S. japonicum infection. This nephropathy may bring clinical changes and leads to severe evolution with letal risk. It may be induced or aggravated by the specific treatment but it has then, in most cases, a short duration and a good prognosis. Specific treatment fixed in order to reduce the amount of circulating antigens may be benefic. In some cases, on the contrary, the nephropathy is not reactive to any specific or symptomatic treatment and has an evolution of its own under the action of various factors; the most important is the hepatosplenic damage. Consequently glomerular function must be controlled in patients with schistosomiasis in order to fix the prognosis and the treatment.

Antigen-Antibody Complex↗
PubMedDate not supplied

Stratification of stage D2 prostate cancer patients by a disease aggressiveness score and its use in evaluating disease response and outcome to combination hormonal treatment (GnRH-A plus flutamide).

Suppression of androgen levels of stage D2 prostate cancer patients has been the prominent treatment for advanced prostate cancer. An arithmetic formula expressing disease aggressivity computed by the pre-treatment levels of alkaline phosphatase (AP), degree of tumor differentiation and number of bone metastases correlated well with disease response and outcome in stage D2 patients treated by chronic administration of the gonadotropin-releasing hormone agonistic analogues (GnRH-As; buserelin) or orchiectomy. In the present study we analyzed retrospectively disease response and outcome in 262 previously untreated stage D2 prostate cancer patients who received combination hormonal treatment (GnRH-A plus flutamide) using this aggressiveness score. Mean value of this aggressiveness score between patients who were grouped with reference to type of disease response according to the criteria established by the National Prostatic Cancer Project (NPCP) was statistically different (Kruskal-Wallis, p > 0.001). Pairwise comparison documented that this was true between all but the stable and progression groups. Linear regression analysis documented significant correlation of this aggressiveness score with length of response and survival (r = 0.59, and 0.45, respectively: p > 0.0001). Analysis of slopes obtained by linear regressions between aggressiveness score and survival in patients treated with GnRH-A plus flutamide and with GnRH-A monotherapy documented that disease response and outcome was superior among patients who received combination hormonal treatment. These data indicate that this aggressiveness score correlated well type of disease response, length of response, and survival with patients given combination hormonal treatment, and as such it can be used as an objective tool for analyzing clinical data.

Analysis of Variance↗